Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Enrollment of pivotal trial for tesmilifene to treat breast cancer completed
November 3rd, 2005
YM BioSciences Inc. (YMI), a cancer product development company, announced that it has completed enrollment in its 700 patient pivotal trial of tesmilifene for the treatment of metastatic and recurrent breast cancer. "We anticipate that the first planned interim analysis of data from this pivotal trial will occur in mid calendar 2006," said Vincent A. Salvatori, executive vice president, YM BioSciences. "If survival results are similar to those in the first tesmilifene phase 3 trial then, through a Special Protocol Assessment agreed to with the FDA (U.S. Food and Drug Administration), the data could be sufficient to seek regulatory approval." The...
Source: Women's Health Weekly (2005-11-03)
|
